Search

everythinglearnresearchcommunity

for

Search:↓

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The post discusses a user's hair loss treatment involving Dutasteride 2.5 mg 5 times per week, Finasteride 1mg 4 times per week, RU58841 daily, and Minoxidil twice daily. A reply suggests that the combination is excessive, particularly the use of both Dutasteride and Finasteride, and labels it as a "chemical castration protocol".

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

Switching to dutasteride as a hair loss prevention treatment, along with minoxidil, dermarolling and nizoral shampoo, and the potential benefits and side effects of using finasteride and/or dutasteride in combination with topical anti-androgens like RU58841.

Users discuss using RU58841 with finasteride, dutasteride, and minoxidil for hair loss, noting reduced itching and effective results. Some users report no side effects, while others experience side effects with dutasteride.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

A user is seeking experiences with adenosine for hair loss, asking about its effectiveness, usage duration, and combination with treatments like minoxidil, finasteride, or RU58841. Another user mentions difficulty sourcing adenosine and comments on the mixed quality of research.

The user experienced severe side effects from finasteride and is considering a combination therapy including Minoxidil, Tretinoin, microneedling, caffeine, and other ingredients. They are also thinking about adding red light therapy and microneedling once per week.

The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.

Dutasteride is a stronger 5AR inhibitor than finasteride and can significantly lower DHT levels. Reduced doses of dutasteride may lower side effects.

The user achieved significant hair regrowth using 0.5mg oral Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil twice daily, Ketoconazole shampoo twice a week, and weekly dermastamping with no side effects. Results were noticeable after 2-3 months, with the best results at 9 months.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

User took Dutasteride, Minoxidil, and Vitamin D for hair loss treatment and saw improvement in 2 months. Vitamin D deficiency played a role in recovery.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

A 40-year-old used minoxidil, dutasteride, RU58841, and microneedling for one year, resulting in noticeable hair regrowth despite initial shedding. They believe having more hair is beneficial for dating at their age and also recommend staying fit, eating well, and sleeping over 8 hours.

The conversation is about the effectiveness of Redensyl for hair loss and whether to continue using Minoxidil alone, despite planning for a hair transplant eventually. The user also mentions using dermarolling, PRP therapy, and Nutrafol.

A 23-year-old male started using Redensyl and Aminexil, along with Tab BTN Ultra and Vitamin D3 supplements, for hair loss. He shared progress pictures after 45-50 days of treatment.

The conversation discusses preventative hair care measures for hair loss, focusing on non-prescription treatments like rosemary, peppermint, castor oils, microneedling, and ketoconazole shampoo. It also touches on the use of finasteride, minoxidil, and RU58841 for those experiencing hair loss.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

The conversation is about finding a trustworthy supplier for Pyrilutamide, a hair loss treatment. The user previously purchased RU58841 from Anagenic and is considering them for Pyrilutamide.

The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.